



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,484	01/17/2006	Nai-Kong V. Cheung	639-C-PCT-US	2140
57545 7590 03/10/2010 LAW OFFICES OF ALBERT WAI-KIT CHAN, PLLC 141-07 20TH AVENUE WORLD PLAZA, SUITE 604 WHITESTONE, NY 11357				
EXAMINER OLSON, ERIC				
ART UNIT		PAPER NUMBER		
1623				
MAIL DATE		DELIVERY MODE		
03/10/2010		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



## UNITED STATES DEPARTMENT OF COMMERCE

## U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10565484	1/17/2006	CHEUNG, NAI-KONG V.	639-C-PCT-US

LAW OFFICES OF ALBERT WAI-KIT CHAN, PLLC  
141-07 20TH AVENUE  
WORLD PLAZA, SUITE 604  
WHITESTONE, NY 11357

## EXAMINER

ERIC S. OLSON

ART UNIT	PAPER
1623	20100305

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

## Commissioner for Patents

The information disclosure statement submitted February 26, 2010, has been fully considered and not found to be the basis for any new grounds of rejection against the claims previously allowed in the notice of allowance submitted January 14, 2010. Specifically, the documents cited in the information disclosure statement concern antitumor effects of the compound Lentinan, which is a beta (1,3) glucan having single glucose monosaccharides attached by beta (1,6) linkages. By contrast, the present claims require that the beta glucan have a side chain comprising two or more glucose units. One of ordinary skill in the art would have had no motivation to modify lentinan in such a manner and no expectation that a beta glucan having side chains of two or more glucose units would retain its anti-cancer and immunostimulating activity.

Therefore the claims are seen to be allowable for the same reasons recited in the notices of allowance submitted September 24, 2009, and January 14, 2010.

/Eric S Olson/  
Examiner, Art Unit 1623